Talaris Therapeutics

United States
Sycamore, Georgia, United States, 40202

Company profile

Talaris Therapeutics company profile

Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.

Business identity

Contact email
[email protected]
Operating status
Closed
Company type
For Profit
Employee range
101-250 employees
Revenue range
$1M-$10M
Founded
2002-01-01, Year

Headquarters

Postal code
40202
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
2
Total equity funding
$215M
Last funding
Series B / $115M / 2020-10-06
Last equity funding
Series B / $115M
Investors
14
Lead investors
3
Founders
1
Articles
35
Exited on
2021-05-06

Founders and investors

Founders

Suzanne Ildstad

Lead investors

Blackstone GroupSurveyor CapitalViking Global Investors

Investors

BlackRockCormorant Asset ManagementLongitude CapitalQiming Venture PartnersQiming Venture Partners USA